{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:12:47Z","timestamp":1792624367454,"version":"4.5.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,2]]},"abstract":"Abstract<\/jats:title>\n \n STUDY QUESTION<\/jats:title>\n What is the frequency of, and predictors for, osteoporosis, fractures, and osteoporosis management (investigation, treatment) in women with premature ovarian insufficiency (POI; menopause &lt;40\u2009years) and early menopause (EM; menopause 40\u201344years)?<\/jats:p>\n <\/jats:sec>\n \n SUMMARY ANSWER<\/jats:title>\n Over the 23-year follow-up duration, at a mean age of 68\u2009years, women with POI\/EM had higher osteoporosis\/fracture risk and prevalence, higher osteoporosis screening and anti-osteoporosis medication use compared to women with usual age menopause; increasing age was predictive of increased risk of osteoporosis\/fracture and menopause hormone therapy (MHT) prior to or at study entry (aged 45\u201350\u2009years) was protective.<\/jats:p>\n <\/jats:sec>\n \n WHAT IS KNOWN ALREADY<\/jats:title>\n Women with POI\/EM have increased risk of osteoporosis and fractures with limited data regarding risk factors for reduced bone density and fractures. Clinical guidelines recommend screening with dual X-ray absorptiometry (DXA) and treatment with MHT for most women with POI\/EM to reduce osteoporosis and fracture risk; however, studies indicate gaps in osteoporosis knowledge, guideline uptake, and management adherence by clinicians and women.<\/jats:p>\n <\/jats:sec>\n \n STUDY DESIGN, SIZE, DURATION<\/jats:title>\n The Australian Longitudinal Study on Women\u2019s Health is a prospective longitudinal study of Australian women. This study uses the cohort of women born between 1946 and 1951, surveyed nine times between 1996 and 2019. Data from the Australian administrative health records, including hospital admissions data (fractures, osteoporosis), Medicare Benefits Schedule (DXA), and the Pharmaceutical Benefits Scheme (PBS; MHT, anti-osteoporosis medication, available only from 2002) were linked to survey data.<\/jats:p>\n <\/jats:sec>\n \n PARTICIPANTS\/MATERIALS, SETTING, METHODS<\/jats:title>\n Survey respondents with self-reported age of menopause were included. POI\/EM was defined as menopause &lt;45\u2009years. T-test or chi-square were used for comparisons at baseline (P\u2009&lt;\u20090.05 indicates significance). Generalized estimating equations for panel data explored predictors for the longitudinal outcomes of osteoporosis, fractures, DXA rates, MHT use, and anti-osteoporosis medication (in women with osteoporosis\/fracture, from Survey 4 onwards only). Univariable regression was performed, and variables retained where P\u2009&lt;\u20090.2, to form the multivariable model, and bootstrapping with 100 repetitions at 95% sampling of the original dataset to ensure robustness of results.<\/jats:p>\n <\/jats:sec>\n \n MAIN RESULTS AND THE ROLE OF CHANCE<\/jats:title>\n Eight thousand six hundred and three women were included: 610 (7.1%) with POI\/EM. Mean (SD) baseline age was 47.6 (1.45) years in the entire cohort and mean (SD) age of menopause was 38.2 (7.95) and 51.3 (3.04) years in women with POI\/EM and usual age menopause, respectively (P\u2009&lt;\u20090.001). Over the 23\u2009years, of women with POI\/EM, 303 (49.7%) had osteoporosis\/fractures, 421 (69.0%) had DXA screening, 474 ever used MHT (77.7%), and 116 (39.1%) of those with osteoporosis\/fractures used anti-osteoporosis medication. Of women with usual age menopause, 2929 (36.6%) had osteoporosis\/fractures, 4920 (61.6%) had DXA screening, 4014 (50.2%) used MHT, and 964 (33.0%) of those with osteoporosis\/fractures used anti-osteoporosis medication. Compared to women with menopause at age \u226545\u2009years and after adjusting for other risk factors, women with POI\/EM had increased risk of osteoporosis (odds ratio [OR] 1.37; 95% CI 1.07\u20131.77), fractures (OR 1.45; 1.15\u20131.81), DXA testing (OR 1.64; 1.42\u20131.90), MHT use (OR 6.87; 5.68\u20138.30), and anti-osteoporosis medication use (OR 1.50; 1.14\u20131.98). In women with POI\/EM women, increasing age was associated with greater risk of osteoporosis\/fracture (OR 1.09; 1.08\u20131.11), and MHT prior to or at study entry (aged 45\u201350\u2009years), was protective (OR 0.65, 0.45\u20130.96). In women with POI\/EM, age (OR 1.11; 1.10\u20131.12), fractures (OR 1.80, 1.38\u20132.34), current smoking (OR 0.60; 0.43\u20130.86), and inner (OR 0.68; 0.53\u20130.88) or outer regional (OR 0.63; 0.46\u20130.87) residential location were associated with DXA screening. In women with POI\/EM, increasing age (OR 1.02; 1.01\u20131.02), and currently consuming alcohol (OR 1.17; 1.06\u20131.28), was associated with having ever used MHT. In the 299 women with POI\/EM and osteoporosis\/fractures, only 39.1% ever received treatment with an anti-osteoporosis medication. Increasing age (OR 1.07; 1.04\u20131.09) and lower BMI (OR 0.95; 0.92\u20130.98) were associated with greater likelihood of treatment with anti-osteoporosis medication.<\/jats:p>\n <\/jats:sec>\n \n LIMITATIONS, REASONS FOR CAUTION<\/jats:title>\n Survey data including age of menopause were self-reported by participants; fracture questions were not included in the 2001 survey, and location or level of trauma of self-reported fractures was not asked. Additional risk\/protective factors such as vitamin D status, calcium intake, and exercise were not able to be included. Due to sample size, POI and EM were combined for all analyses, and we were unable to differentiate between causes of POI\/EM. PBS data were only available from 2004, and hospital admissions data were state-based, with all of Australia were only available from 2007.<\/jats:p>\n <\/jats:sec>\n \n WIDER IMPLICATIONS OF THE FINDINGS<\/jats:title>\n This study supports previous literature indicating increased risk of osteoporosis and fractures in women with POI, and adds evidence for women with POI\/EM, where there was a relative paucity of data. This is the first study to analyse a variety of clinical and demographic risk factors for osteoporosis and fractures in women with POI\/EM, as well as analysing investigation and treatment rates. In these women, using MHT prior to or at study entry, aged 45\u201350\u2009years, was protective for osteoporosis\/fractures; however, having ever used MHT was not, highlighting the importance of early treatment with MHT in these women to preserve bone strength. Although women with POI\/EM and osteoporosis or fractures were more likely to use anti-osteoporosis medications than those with usual age menopause, overall treatment rates are low at &lt;40%, demonstrating a significant treatment gap that should be addressed to reduce future fracture risk.<\/jats:p>\n <\/jats:sec>\n \n STUDY FUNDING\/COMPETING INTEREST(S)<\/jats:title>\n This study was funded by The Australian NHMRC Centre of Research Excellence Women\u2019s Health in Reproductive Life (CRE-WHIRL, project number APP1171592). A.R.J. is the recipient of a National Health and Medical Research Council post-graduate research scholarship (grant number 1169192). P.R.E. is supported by a National Health and Medical Research Council grant 1197958. P.R.E. reports grants paid to their institution from Amgen, Sanofi, and Alexion, honoraria from Amgen paid to their institution, and honoraria from Alexion and Kyowa-Kirin.<\/jats:p>\n <\/jats:sec>\n \n TRIAL REGISTRATION NUMBER<\/jats:title>\n N\/A.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/humrep\/deae037","type":"journal-article","created":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:27:20Z","timestamp":1707524840000},"page":"1013-1022","source":"Crossref","is-referenced-by-count":43,"title":["Bone health in women with premature ovarian insufficiency\/early menopause: a 23-year longitudinal analysis"],"prefix":"10.1093","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8419-7987","authenticated-orcid":false,"given":"A R","family":"Jones","sequence":"first","affiliation":[{"name":"Monash Centre for Health Research and Implementation, Monash University , Melbourne, VIC, Australia"},{"name":"Department of Endocrinology, Monash Health , Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Enticott","sequence":"additional","affiliation":[{"name":"Monash Centre for Health Research and Implementation, Monash University , Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P R","family":"Ebeling","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Monash Health , Melbourne, VIC, Australia"},{"name":"Department of Medicine, School of Clinical Sciences, Monash University , Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9610-5904","authenticated-orcid":false,"given":"G D","family":"Mishra","sequence":"additional","affiliation":[{"name":"Australian Women and Girls\u2019 Health Research Centre, School of Public Health, University of Queensland , Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7609-577X","authenticated-orcid":false,"given":"H T","family":"Teede","sequence":"additional","affiliation":[{"name":"Monash Centre for Health Research and Implementation, Monash University , Melbourne, VIC, Australia"},{"name":"Department of Endocrinology, Monash Health , Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A J","family":"Vincent","sequence":"additional","affiliation":[{"name":"Monash Centre for Health Research and Implementation, Monash University , Melbourne, VIC, Australia"},{"name":"Department of Endocrinology, Monash Health , Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"2024050205543040600_deae037-B1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa022464","article-title":"Bone loss and bone size after menopause","volume":"349","author":"Ahlborg","year":"2003","journal-title":"N Engl J Med"},{"key":"2024050205543040600_deae037-B2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12020-018-1746-6","article-title":"Association between age at menopause and fracture risk: a systematic review and meta-analysis","volume":"63","author":"Anagnostis","year":"2019","journal-title":"Endocrine"},{"key":"2024050205543040600_deae037-B3","author":"Australian Bureau of Statistics","year":"2026"},{"key":"2024050205543040600_deae037-B4","author":"Australian Longitudinal Study on Women\u2019s Health","year":"2022"},{"key":"2024050205543040600_deae037-B5","doi-asserted-by":"crossref","first-page":"e0164638","DOI":"10.1371\/journal.pone.0164638","article-title":"Poor compliance to hormone therapy and decreased bone mineral density in women with premature ovarian insufficiency","volume":"11","author":"Bachelot","year":"2016","journal-title":"PLoS One"},{"key":"2024050205543040600_deae037-B6","doi-asserted-by":"crossref","first-page":"e1000181","DOI":"10.1371\/journal.pmed.1000181","article-title":"Hip fracture incidence in relation to age, menopausal status, and age at menopause: prospective analysis","volume":"6","author":"Banks","year":"2009","journal-title":"PLoS Med"},{"key":"2024050205543040600_deae037-B7","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2019-00192","article-title":"Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis","volume":"104","author":"Barrionuevo","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2024050205543040600_deae037-B8","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1210\/jcem-68-3-548","article-title":"Mechanisms of osteoporosis in adult and adolescent women with anorexia nervosa","volume":"68","author":"Biller","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"2024050205543040600_deae037-B9","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1210\/jc.2010-1502","article-title":"Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass","volume":"96","author":"Bone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2024050205543040600_deae037-B10","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1089\/jwh.1996.5.467","article-title":"Women\u2019s Health Australia: establishment of the Australian longitudinal study on women\u2019s health","volume":"5","author":"Brown","year":"1996","journal-title":"J Womens Health"},{"key":"2024050205543040600_deae037-B11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s12020-017-1435-x","article-title":"Estrogen-based hormone therapy in women with primary ovarian insufficiency: a systematic review","volume":"58","author":"Burgos","year":"2017","journal-title":"Endocrine"},{"key":"2024050205543040600_deae037-B12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.maturitas.2022.09.011","article-title":"Impact of hormone therapy on the bone density of women with premature ovarian insufficiency: a systematic review","volume":"167","author":"Costa","year":"2023","journal-title":"Maturitas"},{"key":"2024050205543040600_deae037-B13","doi-asserted-by":"crossref","first-page":"1547, 1547a","DOI":"10.1093\/ije\/dyv110","article-title":"Cohort profile update: Australian Longitudinal Study on Women\u2019s Health","volume":"44","author":"Dobson","year":"2015","journal-title":"Int J Epidemiol"},{"key":"2024050205543040600_deae037-B14","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1210\/jc.2007-1876","article-title":"Bone mineral density changes during the menopause transition in a multiethnic cohort of women","volume":"93","author":"Finkelstein","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"2024050205543040600_deae037-B15","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3109\/13697137.2014.913284","article-title":"Symptoms, health behavior and understanding of menopause therapy in women with premature menopause","volume":"17","author":"Gibson-Helm","year":"2014","journal-title":"Climacteric"},{"key":"2024050205543040600_deae037-B16","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/cen.14049","article-title":"Identifying and addressing osteoporosis knowledge gaps in women with premature ovarian insufficiency and early menopause: a mixed-methods study","volume":"91","author":"Goh","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2024050205543040600_deae037-B17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/13697137.2019.1574738","article-title":"The global prevalence of primary ovarian insufficiency and early menopause: a meta-analysis","volume":"22","author":"Golezar","year":"2019","journal-title":"Climacteric"},{"key":"2024050205543040600_deae037-B18","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.rbmo.2022.02.006","article-title":"Hormone therapy in women with premature ovarian insufficiency: a systematic review and meta-analysis","volume":"44","author":"Gon\u00e7alves","year":"2022","journal-title":"Reprod Biomed Online"},{"key":"2024050205543040600_deae037-B19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0378-5122(03)00040-9","article-title":"Bone density patterns after normal and premature menopause","volume":"44","author":"Hadjidakis","year":"2003","journal-title":"Maturitas"},{"key":"2024050205543040600_deae037-B20","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/humrep\/dez015","article-title":"Variations in reproductive events across life: a pooled analysis of data from 505 147 women across 10 countries","volume":"34","author":"InterLACE Study Team","year":"2019","journal-title":"Hum Reprod"},{"key":"2024050205543040600_deae037-B21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11657-020-00713-8","article-title":"Osteoporosis and premature ovarian insufficiency: geographic variation in clinicians\u2019 and consumers\u2019 knowledge gaps and barriers to care","volume":"15","author":"Jones","year":"2020","journal-title":"Arch Osteoporos"},{"key":"2024050205543040600_deae037-B22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11657-020-00871-9","article-title":"SCOPE 2021: a new scorecard for osteoporosis in Europe","volume":"16","author":"Kanis","year":"2021","journal-title":"Arch Osteoporos"},{"key":"2024050205543040600_deae037-B23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.maturitas.2019.07.021","article-title":"Management of bone health in women with premature ovarian insufficiency: systematic appraisal of clinical practice guidelines and algorithm development","volume":"128","author":"Kiriakova","year":"2019","journal-title":"Maturitas"},{"key":"2024050205543040600_deae037-B24","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1359\/JBMR.040215","article-title":"Risk factors for incident vertebral fractures in men and women: the Rotterdam Study","volume":"19","author":"Klift","year":"2004","journal-title":"J Bone Miner Res"},{"key":"2024050205543040600_deae037-B25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00404-008-0881-3","article-title":"Factors associated with bone density in young women with karyotypically normal spontaneous premature ovarian failure","volume":"280","author":"Leite-Silva","year":"2009","journal-title":"Arch Gynecol Obstet"},{"key":"2024050205543040600_deae037-B26","first-page":"679","article-title":"Early menarche, nulliparity and the risk for premature and early natural menopause","volume":"32","author":"Mishra","year":"2017","journal-title":"Hum Reprod"},{"key":"2024050205543040600_deae037-B27","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jamacardio.2016.2415","article-title":"Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis","volume":"1","author":"Muka","year":"2016","journal-title":"JAMA Cardiol"},{"key":"2024050205543040600_deae037-B28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/13697137.2021.1917539","article-title":"New insights into the diagnosis and management of bone health in premature ovarian insufficiency","volume":"24","author":"Nguyen","year":"2021","journal-title":"Climacteric"},{"key":"2024050205543040600_deae037-B29","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1089\/jwh.2005.14.808","article-title":"Menstrual and reproductive factors and fracture risk: the Leisure World Cohort Study","volume":"14","author":"Paganini-Hill","year":"2005","journal-title":"J W\u2019men's Health (Larchmt)"},{"key":"2024050205543040600_deae037-B30","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00198-004-1735-x","article-title":"Risk factors associated with incident clinical vertebral and nonvertebral fractures in postmenopausal women: the Canadian Multicentre Osteoporosis Study (CaMos)","volume":"16","author":"Papaioannou","year":"2005","journal-title":"Osteoporos Int"},{"key":"2024050205543040600_deae037-B31","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1210\/jc.2008-1878","article-title":"Bone mineral density in estrogen-deficient young women","volume":"94","author":"Popat","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"2024050205543040600_deae037-B32","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture prevention with zoledronate in older women with osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N Engl J Med"},{"key":"2024050205543040600_deae037-B33","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/jbmr.5650040412","article-title":"Age and bone mass in premenopausal women","volume":"4","author":"Rosenthal","year":"1989","journal-title":"J Bone Miner Res"},{"key":"2024050205543040600_deae037-B34","doi-asserted-by":"crossref","first-page":"860853","DOI":"10.3389\/fendo.2022.860853","article-title":"Abnormal trabecular bone score, lower bone mineral density and lean mass in young women with premature ovarian insufficiency are prevented by oestrogen replacement","volume":"13","author":"Samad","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2024050205543040600_deae037-B35","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ejca.2010.11.024","article-title":"Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809","volume":"47","author":"Shapiro","year":"2011","journal-title":"Eur J Cancer"},{"key":"2024050205543040600_deae037-B36","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/GME.0000000000001756","article-title":"The association between primary ovarian insufficiency and osteoporosis in the Canadian Longitudinal Study on Aging","volume":"28","author":"Shea","year":"2021","journal-title":"Menopause"},{"key":"2024050205543040600_deae037-B37","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1007\/s00198-018-4665-8","article-title":"Menstrual and reproductive factors and risk of vertebral fractures in Japanese women: the Japan Public Health Center-based prospective (JPHC) study","volume":"29","author":"Shimizu","year":"2018","journal-title":"Osteoporos Int"},{"key":"2024050205543040600_deae037-B38","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26488","article-title":"Risk factors and surveillance for reduced bone mineral density in pediatric cancer survivors","volume":"64","author":"Siegel","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"2024050205543040600_deae037-B39","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/GME.0000000000000775","article-title":"Age of menopause and fracture risk in postmenopausal women randomized to calcium + vitamin D, hormone therapy, or the combination: results from the W\u2019men's Health Initiative Clinical Trials","volume":"24","author":"Sullivan","year":"2017","journal-title":"Menopause"},{"key":"2024050205543040600_deae037-B40","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1097\/GME.0000000000000451","article-title":"Effects of self-reported age at nonsurgical menopause on time to first fracture and bone mineral density in the Women\u2019s Health Initiative Observational Study","volume":"22","author":"Sullivan","year":"2015","journal-title":"Menopause"},{"key":"2024050205543040600_deae037-B41","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1471-0528.2012.03324.x","article-title":"Early menopause and risk of osteoporosis, fracture and mortality: a 34-year prospective observational study in 390 women","volume":"119","author":"Svejme","year":"2012","journal-title":"BJOG"},{"key":"2024050205543040600_deae037-B42","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/sj.bmt.1705196","article-title":"Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation","volume":"37","author":"Tauchmanova","year":"2006","journal-title":"Bone Marrow Transplant"},{"key":"2024050205543040600_deae037-B43","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/humrep\/dew027","article-title":"ESHRE Guideline: management of women with premature ovarian insufficiency","volume":"31","author":"The ESHRE Guideline Group on POI;","year":"2016","journal-title":"Hum Reprod"},{"key":"2024050205543040600_deae037-B44","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of The North American Menopause Society","volume":"29","author":"The North American Menopause Society","year":"2022","journal-title":"Menopause"},{"key":"2024050205543040600_deae037-B45","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00198-015-3440-3","article-title":"The National Osteoporosis Foundation\u2019s position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations","volume":"27","author":"Weaver","year":"2016","journal-title":"Osteoporos Int"},{"key":"2024050205543040600_deae037-B46","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1093\/humrep\/dez259","article-title":"Age at natural menopause and development of chronic conditions and multimorbidity: results from an Australian prospective cohort","volume":"35","author":"Xu","year":"2020","journal-title":"Hum Reprod"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/39\/5\/1013\/57365632\/deae037.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/39\/5\/1013\/57365632\/deae037.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T01:58:05Z","timestamp":1714615085000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/39\/5\/1013\/7613529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,2,23]]},"published-print":{"date-parts":[[2024,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deae037","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,1]]},"published":{"date-parts":[[2024,2,23]]}}}